Drug Profile
Research programme: equine encephalitis virus vaccine - Maxygen
Alternative Names: Eastern equine encephalitis virus vaccine - Maxygen; Maxy 829; Maxy-EE; Vaccines against encephalitis alphaviruses - Maxygen; Venezuelan equine encephalitis virus vaccine - Maxygen; Western equine encephalitis virus vaccine - MaxygenLatest Information Update: 02 Apr 2018
Price :
$50
*
At a glance
- Originator Maxygen
- Developer Maxygen; United States Army Medical Research Institute of Infectious Diseases
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Eastern equine encephalomyelitis; Venezuelan equine encephalomyelitis; Western equine encephalitis virus infections
Most Recent Events
- 10 Jun 2013 Discontinued - Preclinical for Encephalitis virus infections in USA (Parenteral)
- 18 Sep 2008 Preclinical development is ongoing
- 18 Sep 2008 This equine encephalitis vaccine programme is available for licensing (http://www.maxygen.com)